AC Immune SA
AC Immune SA (ACIU): 43 pipeline candidates · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
N/A
D/E 2.44 · 0% dilution
Lead: Phase 1/Phase 2
43 candidates
N/A
1 buy · 1 sell (180d)
A transparent, data-derived signal for AC Immune SAacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$236.1M
Cash
$26.8M
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (43 candidates)
| Drug | Phase |
|---|---|
| aci-19764 at dose a1 | Phase 1 |
| aci-19764 at dose a2 | Phase 1 |
| aci-19764 at dose a3 | Phase 1 |
| aci-19764 at dose a4 | Phase 1 |
| aci-19764 at dose a5 | Phase 1 |
| aci-19764 at dose a6 | Phase 1 |
| aci-19764 at dose b1 | Phase 1 |
| aci-19764 at dose b2 | Phase 1 |
| aci-19764 at dose b3 | Phase 1 |
| aci-24.060 at dose a in study part 1a | Phase 1/Phase 2 |
Showing 10 of 43 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
47
Total value held
$69.7M
| Holder | Shares | Value |
|---|---|---|
| bvf inc/il | 19,822,436 | $54.5M |
| wells fargo & company/mn | 1,004,284 | $2.8M |
| millennium management llc | 792,657 | $2.2M |
| renaissance technologies llc | 624,367 | $1.7M |
| blackrock, inc. | 524,278 | $1.4M |
| arrowstreet capital, limited partnership | 405,658 | $1.1M |
| dimensional fund advisors lp | 390,165 | $1.1M |
| citadel advisors llc | 298,233 | $820K |
| point72 asset management, l.p. | 293,200 | $806K |
| northern trust corp | 278,513 | $766K |
Showing top 10 of 47 institutional holders of AC Immune SA. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in AC Immune SA's pipeline?
AC Immune SA (ACIU) has 43 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AC Immune SA's lead drug candidate?
AC Immune SA's most advanced tracked candidate is aci-19764 at dose a1 (Phase 1) for Healthy Participants.
What is AC Immune SA's market capitalization?
AC Immune SA's market capitalization is approximately $236.1M.
Who is the CEO of AC Immune SA?
Dr. Andrea Pfeifer Ph.D. is the chief executive officer of AC Immune SA (ACIU).
Get the full picture on AC Immune SA
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.